Why FUGO’s integrated printing cycle could shift dental manufacturing economics
FUGO Precision 3D is debuting its centrifugal 3D printing tech at LMT LAB DAY 2026. Find out how this could transform dental manufacturing workflows.
Medical Devices & Diagnostics
Pharma & Biotech
CREATE’s in vivo CAR-T achieves full B cell depletion and repeat dosing in primates
CREATE Medicines shows redosable B cell depletion in primates with in vivo CAR-T platform. Find out what this means for autoimmune and oncology therapy.
Pharma & Biotech
What Aquestive Therapeutics’ Anaphylm CRL reveals about human factors scrutiny in emergency-use drug approvals
FDA halts Anaphylm over human factors risks. Find out what this means for non-injectable epinephrine and future anaphylaxis treatments.
Pharma & Biotech
Can ALK-Abelló’s EURneffy launch shift real-world adoption of non-injectable adrenaline in EU schools?
EMA backs EURneffy 1 mg for pediatric anaphylaxis in EU. Discover how needle-free adrenaline could reshape allergy emergency response today.
Features & Analysis
Why Sixty Degrees Pharmaceuticals is betting on retail channels for tafenoquine adoption
Tafenoquine’s retail debut via GoodRx marks a shift in malaria prevention access. Find out what this means for U.S. travel medicine strategy.
Medical Devices & Diagnostics
Trace Biosciences’ LGW16-03 IND approval opens new chapter in nerve-targeted surgical imaging
Trace Biosciences receives IND approval for LGW16-03. Find out what this means for nerve imaging and the future of surgical precision.
Medical Devices & Diagnostics
Cynosure Lutronic sets stage for global Mosaic 3D rollout with IMCAS 2026 momentum
Find out how Cynosure Lutronic’s Mosaic 3D laser device could redefine non-ablative resurfacing after CE mark approval under EU MDR.
Pharma & Biotech
Frontage expands US–China clinical footprint to meet demand for early phase integration
Frontage Laboratories expands US and China early phase clinical sites with radiolabel, BE, and oncology focus. Find out what this means for CRDMOs in 2026.
Pharma & Biotech
Tenacia’s ZTALMY launch shows new blueprint for orphan neurology drugs in China
ZTALMY gains commercial launch in China for CDKL5 seizures. Find out what this means for rare disease drug access and neurology strategy.
Pharma & Biotech
Lilly’s $3.5bn Pennsylvania site will anchor U.S. manufacturing for next-gen injectables including retatrutide
Eli Lilly and Company has announced a $3.5 billion investment to build a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania. The site will focus on producing next-generation weight-loss medicines, including the investigational triple hormone receptor agonist retatrutide. Set to become operational by 2031, this is Lilly’s fourth new U.S. manufacturing site